An update from Ovid Therapeutics ( (OVID) ) is now available.
On March 1, 2025, Ovid Therapeutics expanded its Board of Directors by appointing Stelios Papadopoulos, Ph.D., as a Class I director, increasing the board size from five to six members. Dr. Papadopoulos, a seasoned executive with extensive experience in the biotechnology sector, joins the Audit and Compensation Committees, bringing valuable expertise from his previous roles at Exelixis, Inc., Regulus Therapeutics Inc., and other biopharmaceutical companies. This strategic appointment is expected to enhance Ovid’s governance and potentially strengthen its position in the biotechnology industry.
More about Ovid Therapeutics
Ovid Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for rare neurological conditions. The company is engaged in research and development to address unmet medical needs in this specialized market.
YTD Price Performance: -46.88%
Average Trading Volume: 404,759
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $36.22M
See more data about OVID stock on TipRanks’ Stock Analysis page.